Cellular Uptake, Distribution, and Stability of 10-23 Deoxyribozymes
- 1 October 2002
- journal article
- research article
- Published by Mary Ann Liebert Inc in Antisense and Nucleic Acid Drug Development
- Vol. 12 (5) , 289-299
- https://doi.org/10.1089/108729002761381276
Abstract
The cellular uptake, intracellular distribution, and stability of 33-mer deoxyribozyme oligonucleotides (DNAzymes) were examined in several cell lines. PAGE analysis revealed that there was a weak association between the DNAzyme and DOTAP or Superfect transfection reagents at charge ratios that were minimally toxic to cultured cells. Cellular uptake was analyzed by cell fractionation of radiolabeled DNAzyme, by FACS, and by fluorescent microscopic analysis of FITC-labeled and TAMRA-labeled DNAzyme. Altering DNAzyme size and chemistry did not significantly affect uptake into cells. Inspection of paraformaldehyde-fixed cells by fluorescence microscopy revealed that DNAzyme was distributed primarily in punctate structures surrounding the nucleus and that substantial delivery to the nucleus was not observed up to 24 hours after initiation of transfection. Incubation in human serum or plasma demonstrated that a 3′-inversion modification greatly increased DNAzyme stability (t1/2 ≈ 22 hours) in comparison to the unmodified form (t1/2 ≈ 70 minute). The 3′inversion-modified DNAzymes remained stable during cellular uptake, and catalytically active oligonucleotide could be extracted from the cells 24 hours posttransfection. In smooth muscle cell proliferation assay, the modified DNAzyme targeting the c-myc gene showed a much stronger inhibitory effect than did the unmodified version. The present study demonstrates that DNAzymes with a 3′-inversion are readily delivered into cultured cells and are functionally stable for several hours in serum and within cells.Keywords
This publication has 31 references indexed in Scilit:
- On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acidsGene Therapy, 2001
- Inhibition of hepatitis B virus X gene expression by novel DNA enzymesBiochemical Journal, 2001
- Design of nuclease resistant protein kinase cα DNA enzymes with potential therapeutic applicationJournal of Molecular Biology, 2000
- Polyethylenimine but Not Cationic Lipid Improves Antisense Activity of 3′-Capped Phosphodiester OligonucleotidesAntisense and Nucleic Acid Drug Development, 1999
- Inhibition of bcr-abl Oncogene Expression by Novel Deoxyribozymes (DNAzymes)Human Gene Therapy, 1999
- Growth Inhibition of Cervical Tumor Cells by Antisense Oligodeoxynucleotides Directed to the Human Papillomavirus Type 16 E6 GeneAntisense and Nucleic Acid Drug Development, 1999
- Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosomeChemistry & Biology, 1999
- Intracellular Localization of Oligonucleotides: Influence of Fixative ProtocolsAntisense and Nucleic Acid Drug Development, 1999
- Evaluation of the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide, in a 4-Week Study in CD-1 MiceAntisense and Nucleic Acid Drug Development, 1997
- Fate of cationic liposomes and their complex with oligonucleotive in vivoBiochimica et Biophysica Acta (BBA) - Biomembranes, 1996